A pilot study on ^99m-Tc-3PRGD₂ scintigraphy in diagnosis of brain glioma

The ^99mTc-3PRGD₂ targeted SPECT/CT scanning was of significance m detecting differentiated glioma. In this work, the diagnostic value of ^99mTc-3PRGD₂ scintigraphy in brain glioma was evaluated by the ten clinically verified brain glioma patients after obtaining informed consent. The patients first accepted X-ray imaging to localize the detecting regions before administrating with ^99mTc-3PRGD₂ at a mean radioactivity of 849±115 MBq via single intravenous bolus injection 2 h prior to SPECT/CT imaging. Tumor samples for detecting α_vβ₃ were collected by surgical operations two weeks after the scintigraphy. The results of CT and SPECT scanning were merged and compared. The correlation between tumor occupation (T/N ratio) and α_vβ_p3 expression level were analyzed. The T/N ratios in brain glioma were proportionally correlated to α_vβ₃ positive cell percentage (R²=0.9253, p<0.05). This study primarily evaluated the clinical application of ^99mTc-3PRGD₂ SPECT scintigraphy on brain glioma. The more pathological types and detecting strategies covering a large amount of samples would aid to clarify the potentials. (authors)